These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 35303962)

  • 1. CAR-NK cells for cancer immunotherapy: from bench to bedside.
    Zhang L; Meng Y; Feng X; Han Z
    Biomark Res; 2022 Mar; 10(1):12. PubMed ID: 35303962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future.
    Zhang L; Meng Y; Yao H; Zhan R; Chen S; Miao W; Ma S; Xu X; Li Y; Yu M; Han Y; Su W; Han Z; Wang T; Song B; Wang P; Cai H; Yan J
    Am J Cancer Res; 2023; 13(11):5559-5576. PubMed ID: 38058830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.
    Wang Y; Jin S; Zhuang Q; Liu N; Chen R; Adam SA; Jin J; Sun J
    MedComm (2020); 2023 Dec; 4(6):e422. PubMed ID: 38045827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages.
    Ebrahimiyan H; Tamimi A; Shokoohian B; Minaei N; Memarnejadian A; Hossein-Khannazer N; Hassan M; Vosough M
    Int Immunopharmacol; 2022 May; 106():108587. PubMed ID: 35149294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.
    Lu H; Zhao X; Li Z; Hu Y; Wang H
    Front Oncol; 2021; 11():720501. PubMed ID: 34422667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.
    Marofi F; Al-Awad AS; Sulaiman Rahman H; Markov A; Abdelbasset WK; Ivanovna Enina Y; Mahmoodi M; Hassanzadeh A; Yazdanifar M; Stanley Chartrand M; Jarahian M
    Front Oncol; 2021; 11():673276. PubMed ID: 34178661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
    Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
    Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-NK cells: a promising cellular immunotherapy in lymphoma.
    Khanmohammadi S; Rezaei N
    Expert Opin Biol Ther; 2023 Jan; 23(1):37-47. PubMed ID: 36453808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
    Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
    Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
    Chaudhry K; Dowlati E; Bollard CM
    Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
    [No Abstract]   [Full Text] [Related]  

  • 13. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of natural killer immunotherapy in blood cancers and solid tumors.
    Sayegh M; Ma S; Yu J
    Curr Opin Oncol; 2023 Sep; 35(5):446-452. PubMed ID: 37551952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.
    Zhang B; Yang M; Zhang W; Liu N; Wang D; Jing L; Xu N; Yang N; Ren T
    Cell Death Dis; 2024 Jan; 15(1):50. PubMed ID: 38221520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing natural killer cells to develop next-generation cellular immunotherapy.
    Liu S; Nguyen K; Park D; Wong N; Wang A; Zhou Y
    Chronic Dis Transl Med; 2022 Dec; 8(4):245-255. PubMed ID: 36420177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells.
    Hojjatipour T; Sharifzadeh Z; Maali A; Azad M
    Hum Cell; 2023 Nov; 36(6):1843-1864. PubMed ID: 37477869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.